use of acetyl cystein in prevention of anti-TB drug induced hepatitis
Not Applicable
- Conditions
- drug induced hepatits.Toxic liver disease with hepatic necrosis
- Registration Number
- IRCT201205259855N1
- Lead Sponsor
- Arak University of Medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
age over 50 years; hemodynamic stability (mean arterial blood pressure >70 mmHg or systolic blood pressure >90mmHg ) Exclusion criteria: history of acute or chronic renal and liver failure accordance with the definitions of relevant, Unavailability of information related to liver function in basic mode, use of N- acetylcysteine orally, injected or inhaled during 1 month before the beginning of the study; Experience has confirmed that the incidence of hypersensitivity reactions following oral, intravenous or inhaled N- acetylcysteine; receiving concomitant drugs or compounds with antioxidant effects such as vitamin C, vitamin E; HIV + patients; use of alcohol
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzym and if necessary bilirubin. Timepoint: start of treatment and end of first , second, third and fourth of treatment. Method of measurement: paraclinic measurement and clinical interview.
- Secondary Outcome Measures
Name Time Method Decrease of ESR and CRP. Timepoint: start of tretment and end of first , second,third , fourth of tretment. Method of measurement: lESR and CRP measurement.